What conditions can lurbinectedin treat?

FDA-Approved Use for Lurbinectedin

Lurbinectedin (Zepzelca) treats metastatic small cell lung cancer (SCLC) in adults whose disease has progressed after platinum-based chemotherapy.[1]

How It Fits into SCLC Treatment

Doctors use it as a monotherapy for relapsed SCLC, particularly after prior treatments like topotecan fail. The IMpower133 and other trials showed response rates around 35% in this setting, with median progression-free survival of about 5.3 months.[1][2]

Ongoing or Investigational Uses

Clinical trials explore lurbinectedin for other cancers, including:
- Platinum-resistant ovarian cancer (combined with other agents).
- Triple-negative breast cancer.
- Uterine and cervical cancers.
- Mesothelioma and thymic tumors.

These are not yet approved; phase 2/3 data show mixed response rates (10-30%) but no broad regulatory nods.[3]

Who Makes It and Availability

Jazz Pharmaceuticals and PharmaMar developed it. Approved by FDA in June 2020 under accelerated approval, confirmed via overall survival data in 2021.[1]

Common Patient Questions on Eligibility

Patients need confirmed metastatic SCLC with prior platinum exposure. It's IV-administered every 21 days; ECOG performance status 0-2 required. Not for frontline use or non-small cell lung cancer.[2]

[1]: FDA Label for Zepzelca
[2]: NCCN Guidelines for SCLC
[3]: ClinicalTrials.gov searches for lurbinectedin